Polycyclo Ring System Having The Triazole Ring As One Of The Cyclos Patents (Class 548/257)
  • Patent number: 10752720
    Abstract: Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxybiphenyl benzotriazole structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxybiphenyl benzotriazole structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: August 25, 2020
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Shivkumar Mahadevan, Leilani K. Sonoda, Dola Sinha, Patricia Martin
  • Patent number: 9960294
    Abstract: The invention provides highly fluorescent materials comprising a compound of formula (I): The chromophores are particularly useful for absorption and emission of photons in the visible and near infrared wavelength range. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: May 1, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Mila Rachwal, Michiharu Yamamoto
  • Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Patent number: 9802905
    Abstract: A process for removing impurities from a liquid azole heteroaromatic compound-containing (e.g., triazole-containing) mixture by: (a) providing a liquid azole heteroaromatic compound-containing mixture having impurities; and (b) passing the azole heteroaromatic compound-containing mixture through at least one filtration membrane which is a nanofiltration membrane and/or ultrafiltration membrane having a molecular pore size in the range of from about 200 daltons to about 1 kilodaltons to provide a permeate that is an at least partially purified azole heteroaromatic compound-containing mixture and a retentate with at least some impurities.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 31, 2017
    Assignee: Wincom, Inc.
    Inventors: Peter F. Vogt, James E. Milawski, Michael E. Lees, Alexander J. Wessel
  • Patent number: 9309205
    Abstract: A process for removing impurities from a liquid azole heteroaromatic compound-containing (e.g., triazole-containing) mixture by: (a) providing a liquid azole heteroaromatic compound-containing mixture having impurities; and (b) passing the azole heteroaromatic compound-containing mixture through at least one filtration membrane which is a nanofiltration membrane and/or ultrafiltration membrane having a molecular pore size in the range of from about 200 daltons to about 1 kilodaltons to provide a permeate that is an at least partially purified azole heteroaromatic compound-containing mixture and a retentate with at least some impurities.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: April 12, 2016
    Assignee: Wincom, Inc.
    Inventors: Peter F. Vogt, James E. Milawski, Michael E. Lees, Alexander J. Wessel
  • Patent number: 9242942
    Abstract: Impure aryltriazoles such as benzotriazole and tolyltriazole that are contaminated with dark colored imputities can be purified by conversion to an aryltriazole acid salt by treatment with aqueous acid. The aryltriazole acid salt is water soluble whereas the dark colored impurities are not. The aryltriazole acid salt solution is separated from the dark colored impurities and the aryltriazole is recovered by neutralization with base.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: January 26, 2016
    Inventor: Randolph K Belter
  • Patent number: 9051282
    Abstract: Disclosed are methods of synthesizing triazoles that avoids the use of concentrated acids in favor of carbonic acid generated from CO2 that can be practiced at ambient and/or elevated temperature and/or atmospheric and/or elevated pressures. The disclosed methods also provide a way of synthesizing triazole products that are sufficiently pure and/or of sufficient concentration whereby the reaction product(s) may not require purification or other treatment before being used in, for example, formulating water treatment compositions that will tend to suppress corrosion or as an intermediate product in a more complex synthesis.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 9, 2015
    Assignee: CHEMTREAT, INC.
    Inventors: William H. Henderson, John Richardson
  • Publication number: 20150119578
    Abstract: A process for removing impurities from a liquid azole heteroaromatic compound-containing (e.g., triazole-containing) mixture by: (a) providing a liquid azole heteroaromatic compound-containing mixture having impurities; and (b) passing the azole heteroaromatic compound-containing mixture through at least one filtration membrane which is a nanofiltration membrane and/or ultrafiltration membrane having a molecular pore size in the range of from about 200 daltons to about 1 kilodaltons to provide a permeate that is an at least partially purified azole heteroaromatic compound-containing mixture and a retentate with at least some impurities.
    Type: Application
    Filed: October 28, 2013
    Publication date: April 30, 2015
    Applicant: Wincom, Inc.
    Inventors: Peter F. Vogt, James E. Milawski, Michael E. Lees, Alexander J. Wessel
  • Publication number: 20150118104
    Abstract: Compounds and compositions are used as corrosion inhibitors for pipelines for crude oil containing water with high salt concentrations. The inhibitors are ionic liquids, imidazoles, benzotriazoles, and mixtures thereof. The composition includes two or more members of the inhibitors with a solvent. The inhibitors reduce corrosion of metallic surfaces of the pipelines containing crude oil having 0.2 and 40 wt % water, 10,000 to 70,000 ppm salt, and 9 to 600 ppm hydrogen sulfide. A synergic effect is provided by two or more different inhibitors. This synergy is derived from interactions with the metallic surface, among themselves or with the corrosive medium depending on the chain length, to inhibit the corrosion with decrease of the formulation dose. The composition can be a ternary formulation of the three families or two components of one family and a third component of a different family.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 30, 2015
    Inventors: Jesus MARIN CRUZ, Araceli VEGA PAZ, Luisa Elena MONTIEL SANCHEZ, Salvador CASTILLO CERVANTES, Rafael MARTINEZ PALOU, Arquimedes ESTRADA MARTINEZ, Luis Manuel QUEJ AKE, Jose Luis Rodolfo BENITEZ AGUILAR, Veronica SANCHEZ GARCIA
  • Publication number: 20150005508
    Abstract: Impure aryltriazoles such as benzotriazole and tolyltriazole that are contaminated with dark colored imputities can be purified by conversion to an aryltriazole acid salt by treatment with aqueous acid. The aryltriazole acid salt is water soluble whereas the dark colored impurities are not. The aryltriazole acid salt solution is separated from the dark colored impurities and the aryltriazole is recovered by neutralization with base.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 1, 2015
    Inventor: Randolph Kenneth Belter
  • Patent number: 8912188
    Abstract: Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: December 16, 2014
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Robert C. Kelly
  • Publication number: 20140364594
    Abstract: The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.
    Type: Application
    Filed: July 23, 2014
    Publication date: December 11, 2014
    Inventors: Takamitsu HOSOYA, Isao KII, Suguru YOSHIDA, Takeshi MATSUSHITA
  • Patent number: 8901312
    Abstract: The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: December 2, 2014
    Assignee: JNC Corporation
    Inventors: Takamitsu Hosoya, Isao Kii, Suguru Yoshida, Takeshi Matsushita
  • Patent number: 8883829
    Abstract: The present invention relates to novel benzotriazoles and to novel topical compositions comprising these benzotriazoles. Furthermore, the invention relates to the use of the novel benzotriazoles as photostabilizer and solubilizer for dibenzoylmethane derivatives such as Butyl Methoxydibenzoylmethane. In one aspect the invention relates to novel benzotriazoles of formula (Ia) wherein R2 is hydrogen; C1-30alkyl; C1-5alkoxy; C1-5alkoxycarbonyl; C5-7cycloalkyl; C6-10aryl or aralkyl; R3 is hydrogen; C1-5alkyl; C1-5alkoxy or halogen, preferably hydrogen or Cl; R4 is hydrogen or C1-5alkyl; R5 is C1-30alkyl or C5-10cycloalkyl.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: November 11, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Alexander Schlifke-Poschalko, Christine Mendrok-Edinger, Horst Westenfelder
  • Patent number: 8865731
    Abstract: Provided are: an agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), which comprises a compound having adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof as an active ingredient; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance or constipation; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance; and the like.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: October 21, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Jun Ouchi, Shunji Kunori, Yozo Kojima, Katsumi Shinoda, Katsutoshi Sasaki, Shiro Shirakura
  • Publication number: 20140231715
    Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Application
    Filed: March 23, 2012
    Publication date: August 21, 2014
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Hossain Parham, Thomas Eberle, Teresa Mujica-Fernaud
  • Patent number: 8802053
    Abstract: Radiotracer vorozole compounds for in vivo and in vitro assaying, studying and imaging cytochrome P450 aromatase enzymes in humans, animals, and tissues and methods for making and using the same are provided. [N-radio-methyl] vorozole substantially separated from an N-3 radio-methyl isomer of vorozole is provided. Separation is accomplished through use of chromatography resins providing multiple mechanisms of selectivity.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: August 12, 2014
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Sung Won Kim, Anat Biegon, Joanna S. Fowler
  • Patent number: 8795629
    Abstract: Radiotracer vorozole compounds for in vivo and in vitro assaying, studying and imaging cytochrome P450 aromatase enzymes in humans, animals, and tissues and methods for making and using the same are provided. [N-radio-methyl] vorozole substantially separated from an N-3 radio-methyl isomer of vorozole is provided. Separation is accomplished through use of chromatography resins providing multiple mechanisms of selectivity.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: August 5, 2014
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Sung Won Kim, Anat Biegon, Joanna S. Fowler
  • Patent number: 8785482
    Abstract: The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 22, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas C. Beshore, Scott D. Kuduk
  • Patent number: 8772276
    Abstract: The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Jason W. Skudlarek
  • Publication number: 20140171658
    Abstract: Disclosed are methods of synthesizing triazoles that avoids the use of concentrated acids in favor of carbonic acid generated from CO2 that can be practiced at ambient and/or elevated temperature and/or atmospheric and/or elevated pressures. The disclosed methods also provide a way of synthesizing triazole products that are sufficiently pure and/or of sufficient concentration whereby the reaction product(s) may not require purification or other treatment before being used in, for example, formulating water treatment compositions that will tend to suppress corrosion or as an intermediate product in a more complex synthesis.
    Type: Application
    Filed: December 17, 2012
    Publication date: June 19, 2014
    Applicant: ChemTreat Inc.
    Inventors: William H. Henderson, John Richardson
  • Publication number: 20140088112
    Abstract: The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Scott D. Kuduk, Jason W. Skudlarek
  • Publication number: 20140088150
    Abstract: The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Douglas C. Beshore, Scott D. Kuduk
  • Patent number: 8614229
    Abstract: The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: December 24, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gopinadhan N. Anilkumar, Frank Bennett, Tin-Yau Chan, Kevin X. Chen, Mousumi Sannigrahi, Francisco Velazquez, Srikanth Venkatraman, Qingbei Zeng, Jose S. Duca, Charles A. Lesburg, Joseph A. Kozlowski, F. George Njoroge, Stuart B. Rosenblum, Neng-Yang Shih
  • Patent number: 8598078
    Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: December 3, 2013
    Assignee: Syngenta Crop Protection, LLC
    Inventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
  • Patent number: 8585938
    Abstract: UV absorbing compounds that are effective in blocking UV and short-wavelength blue light are disclosed. The UV absorbing compounds are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 19, 2013
    Assignee: Novartis AG
    Inventors: David L. Jinkerson, Walter R. Laredo
  • Publication number: 20130225831
    Abstract: Radiotracer vorozole compounds for in vivo and in vitro assaying, studying and imaging cytochrome P450 aromatase enzymes in humans, animals, and tissues and methods for making and using the same are provided. [N-radio-methyl] vorozole substantially separated from an N-3 radio-methyl isomer of vorozole is provided. Separation is accomplished through use of chromatography resins providing multiple mechanisms of selectivity.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 29, 2013
    Applicant: Brookhaven Science Associates, LLC
    Inventor: Brookhaven Science Associates, LLC
  • Patent number: 8519074
    Abstract: Polymers including pendent hydrophobic groups and pendent proton transfer groups are shown to form nanostructured films exhibiting greatly increased proton conductivity compared with films prepared from corresponding polymers lacking hydrophobic groups. The polymers can include repeating units each of which has both a hydrophobic group and a proton transfer group. Alternatively, the polymers can be the product of copolymerizing a first monomer with at least one hydrophobic group and a second monomer with at least one proton transfer group. The polymers are useful for the preparation of fuel cell proton exchange membranes.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: August 27, 2013
    Assignee: The University of Massachusettes
    Inventors: Sankaran Thayumanavan, Mark Tuominen, Ryan Hayward
  • Patent number: 8425891
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: April 23, 2013
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Patent number: 8415131
    Abstract: Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: April 9, 2013
    Assignee: University of South Carolina
    Inventors: Qian Wang, Kai Li, Charlene Mello
  • Publication number: 20130074927
    Abstract: The invention provides highly fluorescent materials comprising a single (n=0) or a series (n=1, 2, etc.) of benzo heterocyclic systems. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventor: NITTO DENKO CORPORATION
  • Publication number: 20130029846
    Abstract: The present invention relates to the use of bicyclic amidine compounds of formula I as defined in the description, and the N-oxides, and salts thereof for combating harmful fungi, and also to compositions and seed comprising at least one such compound. The invention also relates to novel bicyclic amidines and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: March 28, 2011
    Publication date: January 31, 2013
    Applicant: BASF SE
    Inventors: Joachim Rheinheimer, Christian Pilger, Stefan Redlich, Doris Kremzow, Claudia Rosenbaum, Burghard Liebmann, Wassilios Grammenos
  • Publication number: 20130011901
    Abstract: The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.
    Type: Application
    Filed: March 9, 2011
    Publication date: January 10, 2013
    Applicant: JNC CORPORATION
    Inventors: Takamitsu Hosoya, Isao Kii, Suguru Yoshida, Takeshi Matsushita
  • Patent number: 8323631
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Patent number: 8324256
    Abstract: Described herein are tri-functional compounds useful in the production of ophthalmic lenses. The compounds are composed of UV absorber having a polymerization initiator directly or indirectly bonded to the ultraviolet absorber, and an olefinic group directly or indirectly bonded to the ultraviolet absorber. Also described herein are polymers and ophthalmic lenses produced from the tri-functional compounds described herein.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventors: Angelika Maria Domschke, Lynn Cook Winterton, Troy Vernon Holland, Richard Charles Turek
  • Patent number: 8324400
    Abstract: This invention is about a material which provides to observe all colors necessary for display technologies in a very small potential range. The material is a derivative of benzotriazole containing donor acceptor type conducting polymer which is soluble, fluorescent and can be used in LEDs, solar cells, electrochromic devices, smart windows and many other technologies.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 4, 2012
    Inventors: Levent Kamil Toppare, Abidin Balan, Derya Baran
  • Patent number: 8314131
    Abstract: The present invention comprises a new class of compounds useful for modulating the activity of p38 MAP kinase. The compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R1 and R5 are defined herein. The invention further provides pharmaceutical compositions including one or more compounds of Formula I, use of such compounds and compositions for treatment of p38 MAP kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 20, 2012
    Assignee: Amgen Inc.
    Inventors: Liping H. Pettus, Kelvin K. C. Sham, Andrew Tasker, Shimin Xu
  • Patent number: 8273877
    Abstract: Substituted tetraazapentalenes have two benzenoid rings and eight substitutable positions. Substitutions are made of hydrogen or C—H groups in favor of amino groups, nitro groups or nitrogen atoms. The tetraazapentalenes are synthesized through an intermediate azo, which is made from a 1:1:1 molar ratio of a nitroaniline, sodium nitrite and an amine.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: September 25, 2012
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Alfred G. Stern, Patrick A. Caruana
  • Patent number: 8262949
    Abstract: The instant invention relates to novel benzotriazole UV-absorbers having a long wavelength shifted absorption spectrum with significant absorbance up to 410-420 nm. Further aspects of the invention are a process for their preparation, a UV stabilized composition containing the new UV-absorbers and the use of the new compounds as UV-light stabilizers for organic materials.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: September 11, 2012
    Assignee: BASF SE
    Inventors: Katharina Fritzsche, Markus Grob, Adalbert Braig, Ilona Marion Kienzle, Gérard Daniel Georges Vilain
  • Patent number: 8262947
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventor: Walter R. Laredo
  • Patent number: 8262948
    Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Walter R. Laredo, Ali E. Akinay
  • Patent number: 8232326
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: July 31, 2012
    Assignee: Novartis AG
    Inventor: Walter R. Laredo
  • Publication number: 20120172392
    Abstract: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 5, 2012
    Inventors: LUISA M. SALTER-CID, ERIC Y. WANG, MARY T. MACDONALD, JINGJING ZHAO
  • Patent number: 8153703
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 10, 2012
    Assignee: Novartis AG
    Inventor: Walter R. Laredo
  • Patent number: 8043607
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: October 25, 2011
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Patent number: 8026360
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: September 27, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jianmin Fu, Vandna Raina, Serguei Sviridov, Vishnumurthy Kodumuru, Nagasree Chakka, Shifeng Lui, Shaoyi Sun, Duanjie Hou
  • Patent number: 7956185
    Abstract: Compounds of formula (I) where X1, C1, and D1 are defined herein, are inhibitors of polo-like kinases. The compounds of formula (I) are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: June 7, 2011
    Assignee: Abbott Laboratories
    Inventors: Robert B. Diebold, Stevan W. Djuric, Vincent L. Giranda, Laura A. Hexamer, Nan-Horng Lin, Julie M. Miyashiro, Thomas D. Penning, Magdalena Przytulinska, Thomas J. Sowin, Gerard M. Sullivan, Zhi-Fu Tao, Yunsong Tong, Anil Vasudevan, Le Wang, Keith W. Woods, Zhiren Xia, Henry Q. Zhang
  • Publication number: 20110118219
    Abstract: Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles(azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable prodrug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia.
    Type: Application
    Filed: March 19, 2009
    Publication date: May 19, 2011
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Vincent C.O. Njar, Angela M.H. Brodie, Lalji K. Gediya
  • Patent number: 7939528
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: May 10, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • Patent number: 7923568
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: April 12, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark L. Greenlee, Dongfang Meng, Dann L. Parker, Jr., Wanying Sun, Kenneth J. Wildonger, Robert R. Wilkening